Brief: PCI Biotech Holding: Completion of the third group of the ENHANCE study

PCI Biotech Holding ASA

20/02/2015 07:02

Feb 20 (Reuters) - PCI Biotech Holding ASA  PCIB.OL :  
    * PCI Biotech (PCIB) reported that the treatment evaluation 
of the third group in the intra-tumour light dose escalation 
part of the ENHANCE study has been completed 
    * ENHANCE is a phase II study of Amphinex in combination 
with the cytotoxic agent bleomycin in recurrent head and neck 
cancer patients 
 
Source text for Eikon:  ID:nHUGhx5cF  
Further company coverage:  PCIB.OL  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48586983920;))